AVGR Avinger Inc

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif.--(BUSINESS WIRE)--

Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq: AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the “IPO”), are encouraged to contact the Firm.

If you purchased Avinger shares on or about the IPO, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or via e-mail at [email protected].

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, Avinger filed documents in connection with the IPO that contained materially false and misleading statements and/or failed to disclose: that Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; that Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result, the Company was experiencing lower sales and revenues. When this information was released, Avinger’s share price dropped, causing investors harm according to the Complaint. On May 3, 2017, the stock closed at $0.57 per share, a decline of over 95% from the IPO price.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

EN
25/05/2017

Underlying

AVGRAvinger Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avinger Inc

 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Reports Third Quarter 2019 Financial Results

Avinger Reports Third Quarter 2019 Financial Results Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended September 30, 2019. Third Quarter Highlights Increased revenue 19% year-...

November 5, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Closes $4.5 Million Equity Offering

Avinger Closes $4.5 Million Equity Offering REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to ...

August 26, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Prices $4.5 Million Underwritten Public Offering of Common Sto...

Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Comp...

August 22, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Announces Proposed Underwritten Public Offering of Common Stoc...

Avinger Announces Proposed Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to ...

August 21, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019 Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Increased revenue 26% from the first quart...

July 31, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch